Historical Product Revenue

Royalty Revenue by Product ($ in 000’s)

Avastin	Q1	Q2	Q3	Q4	Total
2010	16,870	44,765			61,635
2009	13,605	35,161	21,060	15,141	84,966
2008	9,957	30,480	19,574	12,394	72,405
2007	8,990	21,842	17,478	9,549	57,859
2006	10,438	15,572	15,405	12,536	53,952

Herceptin	Q1	Q2	Q3	Q4	Total
2010	23,402	38,555			61,957
2009	16,003	32,331	26,830	18,615	93,779
2008	14,092	34,383	28,122	20,282	96,880
2007	19,035	28,188	22,582	14,802	84,608
2006	15,142	28,188	21,557	20,354	85,241

Lucentis	Q1	Q2	Q3	Q4	Total
2010	7,220	19,091			26,310
2009	4,621	12,863	8,123	6,152	31,759
2008	3,636	11,060	7,631	4,549	26,876
2007	2,931	6,543	6,579	3,517	19,570
2006	–	–	2,866	3,335	6,202

Xolair	Q1	Q2	Q3	Q4	Total
2010	3,723	6,386			10,110
2009	2,665	5,082	4,085	3,722	15,553
2008	1,488	4,866	3,569	2,927	12,850
2007	1,684	3,942	3,332	2,184	11,142
2006	2,263	2,969	3,041	2,495	10,768

Raptiva	Q1	Q2	Q3	Q4	Total
2010	(150)	142			(8)
2009	477	589	22	150	1,238
2008	405	1,618	1,111	802	3,937
2007	588	1,246	1,160	738	3,733
2006	776	1,060	1,069	874	3,780

Synagis	Q1	Q2	Q3	Q4	Total
2010	–	–			–
2009	17,145	18,869	1,568	3,159	40,741
2008	16,268	17,376	2,278	4,251	40,173
2007	14,352	16,747	1,608	4,042	36,748
2006	14,171	14,689	1,608	3,664	34,131

Tysabri	Q1	Q2	Q3	Q4	Total
2010	8,791	8,788			17,579
2009	6,656	7,200	7,642	8,564	30,062
2008	3,883	5,042	5,949	6,992	21,866
2007	839	1,611	2,084	2,836	7,370
2006	–	–	–	237	237

Actemra	Q1	Q2	Q3	Q4	Total
2010	1,587	1,950			3,538
2009	585	537	909	1,197	3,228
2008	44	116	179	369	708
2007	839	326	32	34	425
2006	–	–	–	–	–

Mylotarg	Q1	Q2	Q3	Q4	Total
2010	366	153			519
2009	293	370	805	453	1,921
2008	314	132	288	209	943
2007	276	137	292	426	1,131
2006	309	168	311	568	1,355